Achieve Life Sciences to present 52-week cytisinicline efficacy data from ORCA-OL smoking, e-cigarette cessation trial at CHEST 2026

• Achieve Life Sciences flagged new 52-week trial data on cytisinicline for smoking and e-cigarette cessation for presentation at CHEST 2026.
• Results from the open-label ORCA-OL study are scheduled for Oct. 20, 2026, indicating sustained abstinence during year-long treatment.
• The trial enrolled 475 adults who previously participated in earlier cytisinicline studies and continued to smoke or vape daily.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280830PRIMZONEFULLFEED9834664) on September 28, 2026, and is solely responsible for the information contained therein.